Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ACT-132577 in Severe Renal Impairment
NCT03165071Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jun 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprocitentan in hypertension (HTN), sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration up to 16 days, Area Under the Plasma Concentration-Time Curve (0-t) up to 16 days and 1 more. Started Jun 2017; status: completed.
02
Drugs
aprocitentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03165071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165071.